The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough.

Acute myeloid leukemia (AML) is principally a disease of older patients, with a median age at diagnosis of 68 years. 1 Key Statistics for Acute Myeloid Leukemia (AML). American Cancer Society, Atlanta, GA, USA. Accessed: October 21, 2022. Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html Google Scholar In 2020, the landmark VIALE-A trial led to full FDA approval of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed AML patients age 75 or older, or patients younger than 75 with 1 of several qualifying comorbidities. 2 DiNardo CD Jonas BA Pullarkat V et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383: 617-629 Crossref PubMed Scopus (911) Google Scholar In relatively short order, a new standard-of-care was implemented across the world for the majority of AML patients over the age of 75.